Treatment of primary central nervous system lymphoma with induction of complement-dependent cytotoxicity by intraventricular administration of autologous-serum-supplemented rituximab

Cancer Science

Volumn 97, Issue 1, 2006, Pages 80-83

  Takami, Akiyoshi ^a   Hayashi, Tomoe ^a   Kita, Daisuke ^a   Nishimura, Ryosei ^a   Asakura, Hidesaku ^a   Nakao, Shinji ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; METHOTREXATE; PREDNISOLONE; RITUXIMAB;

ADULT; ARTICLE; BRAIN BIOPSY; BRAIN EDEMA; BRAIN RADIATION; CANCER MORTALITY; CASE REPORT; CELL LINE; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID CYTOLOGY; CEREBROSPINAL FLUID SHUNTING; CLINICAL FEATURE; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPUTER ASSISTED TOMOGRAPHY; DIPLOPIA; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEADACHE; HISTOPATHOLOGY; HUMAN; HYDROCEPHALUS; IMMUNE DEFICIENCY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; SALVAGE THERAPY; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR CELL;

ADULT; ANTIBODIES, MONOCLONAL; CELL LINE; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMPLEMENT SYSTEM PROTEINS; HUMANS; IMMUNOTHERAPY; INJECTIONS, INTRAVENTRICULAR; LYMPHOMA; MALE; SERUM; TOMOGRAPHY SCANNERS, X-RAY COMPUTED;

EID: 32944467293     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2006.00138.x     Document Type: Article

References (20)

1. Reni M, Ferreri AJ. Therapeutic management of primary CNS lymphoma in immunocompetent patients. Expert Rev Anticancer Ther 2001; 1: 382-94.
2. Hoang-Xuan K, Camilleri-Broet S, Soussain C. Recent advances in primary CNS lymphoma. Curr Opin Oncol 2004; 16: 601-6.
3. DeAngelis LM. Primary CNS lymphoma: treatment with combined chemotherapy and radiotherapy. J Neurooncol 1999; 43: 249-57.
4. Reni M, Ferreri AJ, Garancini MP, Villa E. Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Ann Oncol 1997; 8: 227-34.
5. Manches O, Lui G, Chaperot L et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003; 101: 949-54.
6. Harjunpaa A, Junnikkala S, Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 2000; 51: 634-41.
7. Coiffier B, Haioun C, Ketterer N et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92: 1927-32.
8. Foran JM, Rohatiner AZ, Cunningham D et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18: 317-24.
9. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-42.
10. Czuczman MS, Grillo-Lopez AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268-76.
11. Schlegel U, Schmidt-Wolf IG, Deckert M. Primary CNS lymphoma: clinical presentation, pathological classification, molecular pathogenesis and treatment. J Neurol Sci 2000; 181: 1-12.
12. Rubenstein JL, Combs D, Rosenberg J et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003; 101: 466-8.
13. Schulz H, Pels H, Schmidt-Wolf I et al. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica 2004; 89: 753-4.
14. Batchelor T, Carson K, O'Neill A et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 2003; 21: 1044-9.
15. Nishimura R, Goto Y, Maeba H et al. Simultaneous supply of human complement required for an effective treatment of CNS lymphomas with rituximab: therapeutic experimental evidence. Blood 2003; 102: 4958a.
16. Berinstein NL, Grillo-Lopez AJ, White CA et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998; 9: 995-1001.
17. Colombat P, Salles G, Brousse N et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97: 101-6.
18. Selenko N, Maidic O, Draxier S et al. CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells. Leukemia 2001; 15: 1619-26.
19. Neumann H. Control of glial immune function by neurons. Glia 2001; 36: 191-9.
20. Bienvenu J, Chvetzoff R, Salles G et al. Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. Hematol J 2001; 2: 378-84.